Medicines & Healthcare products
Regulatory Agency
- Alerts, recalls and safety information: medicines and medical devices
- Drug Safety Update
- Yellow Card: Report a problem with a medicine or medical device
- Marketing authorisations and licensing guidance
- Product information about medicines
- Medical devices regulation and safety
- Latest information for patients
- MHRA guidance on coronavirus (COVID-19)
- About MHRA
- All MHRA services and information
Featured
Medicines and medical devices: Five top tips for summer
— Press release
Key advice on medicines and medical devices for the holiday season.
MHRA approves Comirnaty JN.1 COVID-19 vaccine for adults and children from infancy
— News story
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 24 July, approved an adapted Pfizer/BioNTech COVID-19 vaccine (Comirnaty) that targets the JN.1 COVID-19 subvariant.
Ocrelizumab approved as an injection to treat multiple sclerosis in adults
— Press release
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new formulation of the medicine ocrelizumab (Ocrevus 920mg solution for injection) to treat relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in adults.
MHRA approves GLP –1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults
— Press release
Semaglutide is the first weight loss drug approved in the UK as a preventative treatment for those with established cardiovascular disease
MHRA approves the first generic raltegravir medicines to treat adult and paediatric patients infected by HIV
— Press release
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 19 July 2024, approved the first generic raltegravir medicines to treat adult and paediatric HIV patients who weigh at least 40kg.
Capivasertib approved to treat patients with advanced breast cancer
— Press release
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 17 July 2024, approved the medicine capivasertib (Truqap) for patients with advanced hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer which has one or more abnormal “PIK3CA”, “AKT1”, or “PTEN” gene, and does not respond to other anti-hormonal-based therapies.
Latest from the Medicines and Healthcare products Regulatory Agency
-
Export medical devices
- Guidance
-
Register medical devices to place on the market
- Guidance
-
Access New Active Substance and Biosimilar Work Sharing Initiatives
- Guidance
See all latest documents
- Get emails
What we do
The Medicines and Healthcare products Regulatory Agency regulates medicines, medical devices and blood components for transfusion in the UK.
MHRA is an executive agency, sponsored by the Department of Health and Social Care.
Read more about what we do
Follow us
Documents
Services
-
Report a problem with a medicine or medical device
-
Check drug analysis profiles (iDAPs)
See all services
Guidance and regulation
-
Find product information about medicines
- Guidance
-
Regulating medical devices in the UK
- Guidance
See all guidance and regulation
News and communications
-
Medicines and medical devices: Five top tips for summer
- Press release
-
MHRA approves Comirnaty JN.1 COVID-19 vaccine for adults and children from infancy
- News story
See all news and communications
Research and statistics
-
Topiramate: review of safety in pregnancy
- Research and analysis
-
Digital mental health technology: user and public perspectives
- Research and analysis
See all research and statistics
Policy papers and consultations
-
Common specification requirements for in vitro diagnostic devices
- Open consultation
-
Impact of AI on the regulation of medical products
- Policy paper
See all policy papers and consultations
Transparency and freedom of information releases
-
Human Medicines Regulations 2012 Advisory Bodies Annual Report 2023
- Corporate report
-
Medicines and Healthcare Products Regulatory Agency Annual Report and Accounts 2023 to 2024
- Corporate report
See all transparency and freedom of information releases
Our management
Dame June Raine DBE
Chief Executive
Amanda Calvert
Interim co-chair
Professor Graham Cooke
Interim co-chair
Michael Whitehouse OBE
Interim co-chair
Liz Booth
Chief People Officer
Rose Braithwaite
Chief Finance Officer
Dr Alison Cave
Chief Safety Officer
Claire Harrison
Chief Digital and Technology Officer
Dr Laura Squire OBE
Chief Healthcare Quality & Access Officer
Dr Glenn Wells
Chief Partnerships Officer
Rachel Bosworth
Director of Communications and Engagement
Mick Foy
Director of Delivery
Carly McGurry
Director of Governance
Nicola Rose
Interim Executive Director, Science and Research
James Pound
Interim Executive Director, Innovation and Compliance
Contact MHRA
General enquiries
10 South Colonnade
London
E14 4PU
United Kingdom
info@mhra.gov.uk
Telephone
020 3080 6000
Fax
020 3118 9803
Office hours are Monday to Friday, 9am to 5pm.
Media enquiries
MHRA
10 South Colonnade
London
E14 4PU
United Kingdom
newscentre@mhra.gov.uk
During office hours:
020 3080 7651 (08:30 - 17:00)
Out of office hours:
07770 446 189 (17:00 - 08:30)
Office hours are Monday to Friday, 8:30am to 5pm. For real-time updates including the latest press releases and news statements, see our Twitter channel at https://www.twitter.com/mhragovuk.
Make an FOI request
- Read about the Freedom of Information (FOI) Act and how to make a request.
- Check our previous releases to see if we’ve already answered your question.
- Make a new request by contacting us using the details below.
Freedom of Information
10 South Colonnade
London
E14 4PU
United Kingdom
info@mhra.gov.uk
Corporate information
- Accessible documents policy
- Complaints procedure
- Our energy use
- Our governance
- Terms of reference
Jobs and contracts
- Procurement at MHRA
- Working for MHRA
- Jobs
Read our policy on Social media use.
